SE469594B - Nukleinsyraderivat - Google Patents
NukleinsyraderivatInfo
- Publication number
- SE469594B SE469594B SE8605616A SE8605616A SE469594B SE 469594 B SE469594 B SE 469594B SE 8605616 A SE8605616 A SE 8605616A SE 8605616 A SE8605616 A SE 8605616A SE 469594 B SE469594 B SE 469594B
- Authority
- SE
- Sweden
- Prior art keywords
- nucleic acid
- poly
- present
- acid derivatives
- sample
- Prior art date
Links
- 108020004707 nucleic acids Proteins 0.000 claims description 97
- 102000039446 nucleic acids Human genes 0.000 claims description 97
- 150000007523 nucleic acids Chemical class 0.000 claims description 97
- 239000002253 acid Substances 0.000 claims description 27
- 229920000642 polymer Polymers 0.000 claims description 19
- 125000004434 sulfur atom Chemical group 0.000 claims description 14
- 125000002740 cytidyl group Chemical group 0.000 claims description 9
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 229920002477 rna polymer Polymers 0.000 claims description 3
- 238000012360 testing method Methods 0.000 description 59
- 239000000523 sample Substances 0.000 description 52
- 210000004027 cell Anatomy 0.000 description 24
- 230000000694 effects Effects 0.000 description 22
- 230000001766 physiological effect Effects 0.000 description 17
- 239000000126 substance Substances 0.000 description 16
- 206010028980 Neoplasm Diseases 0.000 description 14
- 230000002401 inhibitory effect Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 239000013068 control sample Substances 0.000 description 13
- 210000004881 tumor cell Anatomy 0.000 description 13
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 102000003390 tumor necrosis factor Human genes 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 9
- 102000000588 Interleukin-2 Human genes 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 8
- 238000004132 cross linking Methods 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000001939 inductive effect Effects 0.000 description 8
- ZLOIGESWDJYCTF-UHFFFAOYSA-N 4-Thiouridine Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-UHFFFAOYSA-N 0.000 description 7
- ZLOIGESWDJYCTF-XVFCMESISA-N 4-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=S)C=C1 ZLOIGESWDJYCTF-XVFCMESISA-N 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000002504 physiological saline solution Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000002540 macrophage Anatomy 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 241000283973 Oryctolagus cuniculus Species 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 239000011630 iodine Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 230000036961 partial effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000002054 transplantation Methods 0.000 description 4
- 102000000589 Interleukin-1 Human genes 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 3
- XCCTYIAWTASOJW-UHFFFAOYSA-N UDP-Glc Natural products OC1C(O)C(COP(O)(=O)OP(O)(O)=O)OC1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-UHFFFAOYSA-N 0.000 description 3
- XCCTYIAWTASOJW-XVFCMESISA-N Uridine-5'-Diphosphate Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(=O)NC(=O)C=C1 XCCTYIAWTASOJW-XVFCMESISA-N 0.000 description 3
- 238000000862 absorption spectrum Methods 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 230000036760 body temperature Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000002799 interferon inducing agent Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000001698 pyrogenic effect Effects 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- GJTBSTBJLVYKAU-XVFCMESISA-N 2-thiouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=S)NC(=O)C=C1 GJTBSTBJLVYKAU-XVFCMESISA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 101001066878 Homo sapiens Polyribonucleotide nucleotidyltransferase 1, mitochondrial Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 230000006051 NK cell activation Effects 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- OGVPOARJPKSLBM-XVFCMESISA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-(2-oxo-4-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=O)NC(=S)C=C1 OGVPOARJPKSLBM-XVFCMESISA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229920000140 heteropolymer Polymers 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000004303 peritoneum Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- 238000010600 3H thymidine incorporation assay Methods 0.000 description 1
- VABISHCLVYMGAU-UHFFFAOYSA-N 7,9-dihydropurine-8-thione Chemical compound N1=CN=C2NC(S)=NC2=C1 VABISHCLVYMGAU-UHFFFAOYSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000849720 Homo sapiens Ribonuclease P protein subunit p40 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102000002681 Polyribonucleotide nucleotidyltransferase Human genes 0.000 description 1
- 102100034410 Polyribonucleotide nucleotidyltransferase 1, mitochondrial Human genes 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 102100033789 Ribonuclease P protein subunit p40 Human genes 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- BMJOHSBBMARQHC-XVFCMESISA-N [(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-oxo-2-sulfanylidenepyrimidin-1-yl)oxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound O1[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@H](O)[C@@H]1N1C(=S)NC(=O)C=C1 BMJOHSBBMARQHC-XVFCMESISA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- IERHLVCPSMICTF-XVFCMESISA-N cytidine 5'-monophosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(O)=O)O1 IERHLVCPSMICTF-XVFCMESISA-N 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000004368 gonadotroph Anatomy 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- -1 inhalation Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 238000005987 sulfurization reaction Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP107686 | 1986-01-06 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8605616D0 SE8605616D0 (sv) | 1986-12-30 |
| SE8605616L SE8605616L (sv) | 1987-07-07 |
| SE469594B true SE469594B (sv) | 1993-08-02 |
Family
ID=11491410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8605616A SE469594B (sv) | 1986-01-06 | 1986-12-30 | Nukleinsyraderivat |
Country Status (11)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6545138B1 (en) | 1998-05-25 | 2003-04-08 | Nippon Shinyaku Co., Ltd. | Process for producing composite preparation containing nucleic acid |
| WO2003023031A1 (fr) * | 2001-09-04 | 2003-03-20 | Nippon Shinyaku Co., Ltd. | Methode d'evaluation de l'efficacite d'une therapie aux acides nucleiques |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB906851A (en) * | 1960-05-03 | 1962-09-26 | Schwarz Bio Res Inc | Thiolation of polymers |
| DE2041735A1 (de) * | 1970-08-22 | 1972-02-24 | Merck Patent Gmbh | Thio-pyrimidin-derivate |
| GB1364987A (en) * | 1971-06-19 | 1974-08-29 | Merck Patent Gmbh | Biologically active two component complexes |
| GB2038628A (en) * | 1978-11-14 | 1980-07-30 | Searle & Co | Physiological compositions comprising poly(4-thiouridylic acid) or copolymers thereof and the use thereof as anti-viral agents or serum cholesterol lowering agents |
-
1986
- 1986-11-25 JP JP61280452A patent/JPS62252798A/ja active Pending
- 1986-12-30 SE SE8605616A patent/SE469594B/sv not_active IP Right Cessation
- 1986-12-31 FR FR8618433A patent/FR2596762B1/fr not_active Expired - Fee Related
- 1986-12-31 BE BE0/217694A patent/BE906157A/fr not_active IP Right Cessation
-
1987
- 1987-01-05 ES ES8700012A patent/ES2004038A6/es not_active Expired
- 1987-01-05 DE DE19873700164 patent/DE3700164A1/de active Granted
- 1987-01-06 CH CH23/87A patent/CH671960A5/de not_active IP Right Cessation
- 1987-01-06 CA CA000526797A patent/CA1315717C/en not_active Expired - Fee Related
- 1987-01-06 GB GB8700183A patent/GB2185026B/en not_active Expired - Fee Related
- 1987-01-06 NL NL8700016A patent/NL8700016A/nl not_active Application Discontinuation
- 1987-01-06 KR KR1019870000061A patent/KR940004076B1/ko not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| GB2185026B (en) | 1990-08-08 |
| KR940004076B1 (ko) | 1994-05-11 |
| CA1315717C (en) | 1993-04-06 |
| DE3700164A1 (de) | 1987-07-09 |
| FR2596762B1 (fr) | 1993-10-08 |
| SE8605616L (sv) | 1987-07-07 |
| GB2185026A (en) | 1987-07-08 |
| NL8700016A (nl) | 1987-08-03 |
| DE3700164C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1993-02-25 |
| FR2596762A1 (fr) | 1987-10-09 |
| BE906157A (fr) | 1987-07-01 |
| GB8700183D0 (en) | 1987-02-11 |
| JPS62252798A (ja) | 1987-11-04 |
| KR870007198A (ko) | 1987-08-17 |
| SE8605616D0 (sv) | 1986-12-30 |
| CH671960A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1989-10-13 |
| ES2004038A6 (es) | 1988-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1491201B1 (en) | Methods of reducing toxicity of 5-fluorouracil with acylated pyrimidine nucleosides | |
| JP2590248B2 (ja) | 抗ウイルス・抗腫瘍・抗転移・免疫系増強ヌクレオシド類およびヌクレオチド類 | |
| CA2111571C (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides | |
| UA45964C2 (uk) | 2,4-ДИСУЛЬФОНІЛ-<font face="Symbol">a</font>-ФЕНІЛ-ТРЕТ-БУТИЛНІТРОН (ВАРІАНТИ), ЙОГО СОЛІ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ (ВАРІАНТИ), СПОСІБ ЛІКУВАННЯ ПАЦІЄНТА (ВАРІАНТИ) | |
| SE462261B (sv) | Farmaceutisk komposition och konjugat av melfalan och normalt humanimmunoglobulin med antitumoerverkan samt foerfarande foer dess framstaellning | |
| PL186949B1 (pl) | Fizjologicznie czynny koniugat PEG-IFN-alfa, sposób jego wytwarzania oraz zawierające go kompozycjefarmaceutyczne | |
| WO1999042099A1 (en) | Low molecular weight compounds administered together with anti-cancer agents to treat cancer and pharmaceutical compositions thereof | |
| US5298614A (en) | Size limited double stranded poly I poly(cytidylate/4-thiouridylate) | |
| EP4331614A1 (en) | Use of medicament in treatment of tumor disease | |
| DE102005009084A1 (de) | Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel | |
| Parker et al. | N-Trifluoroacetyladriamycin-14-valerate: additional mouse antitumor and toxicity studies | |
| Alexander et al. | Lipid nucleoside conjugates for the treatment of cancer | |
| SE469594B (sv) | Nukleinsyraderivat | |
| Covey et al. | Comparison of the in vitro cytotoxicity (L1210) of 5-aza-2′-deoxycytidine with its therapeutic and toxic effects in mice | |
| JPH07277964A (ja) | 抗腫瘍剤 | |
| US20090270340A1 (en) | Methods of administering antitumor agent comprising deoxycytidine derivative | |
| US6762174B1 (en) | Low molecular weight compounds administered together with anti-cancer agents to prevent or treat cancer and pharmaceutical compositions thereof | |
| US4882147A (en) | Novel polynucleotide analogs, methods for inhibiting nucleic acid polymerases and methods for inducing synthesis of interferon | |
| DE10005275A1 (de) | Neuartige Glycokonjugate | |
| GB2207432A (en) | Nucleic acid derivatives | |
| Ensminger et al. | Thymidine 5′-o-pivaloate: A prodrug derivative of thymidine with potential applications in high-dose methotrexate therapy | |
| HK1003424B (en) | Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8605616-5 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |
Ref document number: 8605616-5 Format of ref document f/p: F |